AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05524597 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Writing Intervention
Description: Participants will be asked to write about different kinds of experiences.
Study NCT05897580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability - Biofeedback (HRV-BF)
Description: The HRV-BF was delivered over 30 minutes once weekly for 8 weeks by our nurse-led Community Health Worker (RN/CHW) team trained to deliver scripted material created by a trained biofeedback practitioner on our study team. The weekly sessions included the use of a tablet device to share a 10-minute video which teaches the basic techniques and breathing practices of HRV-BF and guiding the participant through a 20-minute practice, using the techniques while watching their heart rate data in real time using an HRV-BF device, the EmWave Pro (HeartMath).~Participants were also asked to complete daily practices on their own, without the HRV-BF device, for 10 minutes, twice a day, to reinforce topics and skills taught in videos. Practices logged by the participant were collected weekly by the CHW and referral to resources were provided.
Study NCT05897580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion (HP)
Description: The HP active control group was delivered over 30 minutes, once weekly for 8 weeks by our nurse-led Community Health Worker team, trained to deliver scripted materialized content created. In the HP program, PEH were educated on common physical chronic diseases PEH experience, including hypertension, diabetes, heart disease and arthritis, along with referrals provided based on needs expressed by PEH.
Study NCT05232708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Study NCT05232708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D, 1.0 mg/mL
Description: Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.
Study NCT05460065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single E4 30 mg
Description: Administration of a single intravenous (i.v.) infusion of estetrol (E4) 30 mg (n=6)
Study NCT05460065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single E4 100 mg
Description: Administration of a single i.v. infusion of E4 100 mg (n=6)
Study NCT05460065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple E4 100 mg
Description: Administration of an i.v. infusion of E4 100 mg (or lower dose, depending on single dose results) once a day for 5 consecutive days (n=8)
Study NCT05460065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort A: Single dose of placebo (n=2);~Cohort B: Single dose of placebo (n=2);~Cohort C: multiple dose of placebo (n=4)
Study NCT05435508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: A total of 1 PNE sessions (Neuroscience pain education) will be carried out, in addition medical treatment similar to control group (Usual care). The PNE sessions will be conducted by an experienced PNE certified proffesional in 35 minute face-to-face sessions. In PNE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
Study NCT05435508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group (Usual care) is treated with pre-anesthetic assessment + usual treatment, management for analgesic medication pre, during and post hysterectomy. Depending on the medical needs and criteria of patients´s care physician.
Study NCT06341478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
Study NCT06341478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: various neoadjuvant therapies
Description: Radical cystectomy, Sacituzumab Govitecan (SG), SG + pembrolizumab, nivolumab+abraxane
Study NCT03473288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
Study NCT03473288 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sedentary
Description: Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
Study NCT05916365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously
Study NCT05182749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bacteriophage
Description: A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
Study NCT05182749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered with sodium bicarbonate solution
Study NCT05995106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart4U
Description: Mobile app.
Study NCT05393102 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT05048277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Consultation
Description: Single-Session Consultation (SSC) is a low-intensity, goal-directed, solution-focused counseling service used for treatment of mental health problems. The intervention consists of a 60-minute session conducted through NYU ZOOM, a HIPAA compliant teleconferencing platform. Sessions will be conducted between a parent and a study consultant. The consultant will 1) identify the participant's specific modifiable goal (and associated hope); 2) the smallest-possible step taken to overcome their problem; and 3) work collaboratively in creating an Action Plan, drawing on their inner abilities and external resources. This intervention does not act as therapy but instead, to potentially jumpstart progress and facilitate hope and agency. Following completion, participants will receive their Action Plan. Additional personalized resources will be provided following completion of the follow-up assessment, which includes referrals for further services and online resources.
Study NCT05969834 — intervention group
Intervention type: DRUG
Intervention: uHCG
Description: Final oocyte maturation will be triggered by IM administration of 10000 IU of uHCG (Choriomon)
Study NCT05969834 — intervention group
Intervention type: DRUG
Intervention: rHCG
Description: Final oocyte maturation will be triggered by SC administration of 6500 IU of rHCG (Ovitrelle)
Study NCT05969834 — intervention group
Intervention type: DRUG
Intervention: uHCG and GnRHa
Description: Final oocyte maturation will be triggered by combined SC administration of 0.1 mg of GnRHa (Decapeptyl, Triptorelin) and IM administration of 2500 IU of uHCG (Choriomon)
Study NCT04856800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 20 g protein of whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients)
Study NCT04856800 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains \<1 kcal and 0 g protein
Study NCT05064436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-BMS-986196
Description: Specified dose on specified days
Study NCT04764422 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% normal saline for injection
Study NCT04764422 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-HXP-S vaccine
Description: Vaccine NDV-HXP-S, manufactured by GPO with or without adjuvant CpG1018.
Study NCT06129708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: The aquatic exercises included 5 minutes of warming up in form of walking and running in water, 20 minutes of aerobic and strengthening exercises of pelvis, abdominal and thigh muscles (Double-leg Squat, lunge, knee flexion and extension, hip flexion and
Study NCT06129708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The exercise protocol consists of 5 minute warm up, 35 min aerobic exercise and 5 minute cool-down. Exercises high-intensity treadmill-based treatment for primary dysmenorrhea for three days a week ,The Borg Rating of Perceived Exertion (RPE) Scale from 6 ('no exertion at all') to 20 ('maximal exertion') was used to regulate the exercise intensity on the treadmill. Participants were encouraged to increase the speed of the treadmill until they perceived their RPE to be between 14 and 16. or at a perceived exertion of 11.0 (Borg scale) for the first five minutes (warm-up period), followed by aerobic exercise at 70-85% of maximum heart rate (MHR) (16.0-18.0 Borg scale) for 30 minutes. At the end of the exercise session, women completed a 5-minute cool-down (11.0 Borg scale).
Study NCT04087109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic decision support for deprescribing (MedSafer tool)
Description: During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
Study NCT04445896 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interview
Description: Qualitative Interview to explore thoughts and feelings related to previous discussions around care at end of life
Study NCT05353153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: Hypnosis-based intervention with two sessions of hypnosis (focusing on the treatment of anxiety)
Study NCT05353153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standart care
Description: no intervention no hypnosis
Study NCT05971082 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Follow-up study of progression/remission of liver disease
Study NCT06516380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined treatment of Cyberdyne HAL single joint with TecnoBody D-Wall and Walker View 3.0 SCX devices
Description: HAL-SJ sessions were conducted 5 days a week for 3 months and 2 hours a day for a total of 60 sessions. HAL-SJ application was performed in cybernic voluntary control (CVC) mode for 90 minutes. In addition to each HAL-SJ session, balance exercises were performed with TecnoBody D-Wall for 30 minutes net.
Study NCT06088784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-399A
Description: Orally administered drug in capsule form.
Study NCT06088784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered drug in capsule form.
Study NCT04754048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo NPWT System
Description: Wound treatment with Avance Solo NPWT System for up to 28 days.
Study NCT06383533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Plus Cadonilimab
Description: Disitamab Vedotin: 2.0mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Cardonilimab: 6mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle.
Study NCT05950074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: It´s Up To You program
Description: The main goal of this program is to prevent substance use and engagement in addictive behaviors through enabling teenagers to make informed and responsible decisions. It seeks to support students in the anticipation of realistic choice situations and problems typically affecting this age group. It is based on social influences, considering the peer group influences (peer pressure) and the affective and cognitive factors that intervene at the time of decision-making and problem-resolution. This program is intended to be delivered by trained teachers in six sessions through six different modules.
Study NCT00279487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Study NCT00279487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT06410092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTL001
Description: IV infusion every 2 weeks
Study NCT04663282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study NCT04663282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study NCT05394155 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
Study NCT06020820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Rehabilitation program (Intervention Group) Group A
Description: (Positional release technique on trapezius muscle): the therapist locate and apply pressure along the tender points in the upper fibers of the trapezius. Lateral flexion of subject's head toward the side of a tender point held for 90 seconds.~(Suboccipital muscle release): The therapist places both his palms under the sub occipital region of the subject with his curled-up fingers and places an upward pressure causing a stretch and distraction for 30 seconds,This technique was performed 3 times in one session.~Stretching of pectoralis muscle:~Pectoralis muscle stretch were performed once daily, completing three repetitions on each side with a 30-second hold. Stretching with repetition of five, three times a day for 1week neck and soulder ROMs
Study NCT06020820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group group B
Description: 1. Relax shoulders and neck sufficiently~2. look down~3. turn face to the right~4. turn face to the left~5. incline head to the right~6. incline head to the left~7. turn shoulders round and round~8. slowly raise hands fully then lower them. patients were asked to perform five repetitions of each stretching exercise, three times per day (morning, afternoon, and evening).
Study NCT05586438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin Sulfomethate
Description: The patients receive colistin 150 mg intravenous once daily on non-dialysis day and receive colistin 150 mg intravenous every 12 hours on dialysis day
Study NCT04871646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-314+SOC
Description: CKD-314 is administered intravenously and standard of care is also performed.
Study NCT04871646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CKD-314 Placebo+SOC
Description: CKD-314 placebo is administered intravenously and standard of care is also performed..
Study NCT05386771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey/collagen protein blend
Description: Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
Study NCT05386771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey/collagen protein blend
Description: Ingestion of 30g of protein dissolved in 300ml water consumed after an exercise session
Study NCT05386771 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: A single resistance exercise session of the leg press and leg extension exercise
Study NCT05386771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: A single resistance exercise session of the leg press and leg extension exercise
Study NCT05537662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care neuromodulation therapy (SCS or DRG)
Description: Standard SCS or DRG therapy
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Energy Restriction (CER)
Description: Energy intake will be prescribed at approximately 1,200-1,500 kcal/day with high protein. The diet will consist of low-calorie shakes provided by the study, as well as commercially available portion-controlled entrées, fruits/vegetables, and low energy-density foods available in grocery stores.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate Day Modified Fasting (ADMF)
Description: Enhanced Care participants will have an alternate between three days of very-low energy intake (VLED; approximately 600-800 kcal/d) and four days of healthy eating (HE) each week. On HE days, participants will consume foods ad libitum for satiety.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Health Education Sessions
Description: Using video conferencing, all participants will attend weekly approximately 45-60 minutes group health education sessions led by a registered dietitian. The session will deliver a comprehensive nutritional and lifestyle change program to promote lifestyle changes and improve compliance.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Evening Snack
Description: The participants will have a late evening snack with a protein supplement.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: All participants will be prescribed moderate-intensity aerobic activities that do not require access to specialized exercise facilities.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Weekly data related to adherence, food intake, physical activity, weight measurement, and nonserious adverse events will be self-reported via a REDCap survey. Participants will also be provided with a wireless activity tracker to measure total physical activity and intensity of activity objectively. These data will be used to counsel participants in addition to providing valuable feasibility data.
Study NCT05367596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely Supervised Exercise Sessions
Description: Sessions of 45 minutes duration will be delivered via video conferencing 2-3 times per week.
Study NCT05174403 — intervention group
Intervention type: OTHER
Intervention: Cerebral and spinal cord magnetic resonance imaging
Description: Cerebral and spinal cord magnetic resonance imaging (without injection of contrast medium).~Patient's data will be compared to calibrated data from the commercially available medical software Brain Quant (licence BT-BQ-001-START, market CAIH, CE12331).
Study NCT06012552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Tianesal 12,5mg
Study NCT06012552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: application as in the control group
Study NCT05064137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monomeric self - assembling peptide P11-4
Description: Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
Study NCT05064137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate fluoride varnish, 5% F-
Description: Tricalcium phosphate fluoride varnish, 5% F- ( Clinpro White Varnish ) is a remineralizing agent applied on tooth surface after mixing it with a brush onto the dosage guide.
Study NCT05064137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish (5% sodium fluoride)
Description: fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
Study NCT05654818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 100,000 UI
Study NCT05654818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is identical in appearance to the active treatment: a drinkable solution in ampoules that is clear, yellowish in color with a slightly lemony odor and an oily, slightly sweet, lemony taste.
Study NCT06379815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Lactate
Description: See arm/group description.
Study NCT06379815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: See arm/group description.
Study NCT05133141 — intervention group
Intervention type: DEVICE
Intervention: Echelon Contour
Description: There is no intervention, beyond necessary clinical care, in this study. Echelon Contour is used for transection and resection in colorectal surgical procedures per its instructions for use (IFU).
Study NCT06003049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: BOTOX injection series
Study NCT06003049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection series
Study NCT06003894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kegel exercises
Description: Kegel exercises; It is done by squeezing your pelvic floor muscles for 3 to 5 seconds and relaxing them. Participants are expected to do this exercise in the form of hold-relax 10-15 times each set. Participants are expected to practice Kegel exercises, 2 sets a day, 3 days a week for 8 weeks.